JP2014516924A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516924A5
JP2014516924A5 JP2014504013A JP2014504013A JP2014516924A5 JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5 JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
less
citrate
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032462 external-priority patent/WO2012138958A1/en
Publication of JP2014516924A publication Critical patent/JP2014516924A/ja
Publication of JP2014516924A5 publication Critical patent/JP2014516924A5/ja
Pending legal-status Critical Current

Links

JP2014504013A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014516924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473121P 2011-04-07 2011-04-07
US61/473,121 2011-04-07
PCT/US2012/032462 WO2012138958A1 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014516924A JP2014516924A (ja) 2014-07-17
JP2014516924A5 true JP2014516924A5 (https=) 2016-01-28

Family

ID=46969561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504013A Pending JP2014516924A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140023655A1 (https=)
EP (2) EP3058952A1 (https=)
JP (1) JP2014516924A (https=)
KR (1) KR20140018966A (https=)
CN (1) CN103596585A (https=)
AU (2) AU2012240050B2 (https=)
BR (1) BR112013025866A2 (https=)
CA (1) CA2832556A1 (https=)
EA (1) EA201391488A1 (https=)
IL (1) IL228591A0 (https=)
SG (1) SG193963A1 (https=)
WO (1) WO2012138958A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501364A1 (en) * 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
WO2014169153A1 (en) * 2013-04-10 2014-10-16 Echogen, Inc. Peptide complexes and therapeutic uses
JP6179939B2 (ja) * 2013-07-09 2017-08-16 国立大学法人 筑波大学 高濃度γグロブリン製剤の粘度低下方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3804747A1 (en) * 2015-01-18 2021-04-14 Gloriana Therapeutics, Inc. Therapeutic protein formulations
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
AU2020251627A1 (en) 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
JP2023533704A (ja) * 2020-07-13 2023-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ
KR20230167968A (ko) * 2022-06-03 2023-12-12 주식회사 녹십자홀딩스 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
CA2503946C (en) * 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PH12012501364A1 (en) * 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2011095543A1 (en) * 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EA201391489A1 (ru) * 2011-04-07 2014-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью

Similar Documents

Publication Publication Date Title
JP2014516924A5 (https=)
JP2014510152A5 (https=)
KR102462041B1 (ko) 암 치료용 담체-pd-l1 결합제 조성물
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
ES2885815T3 (es) Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento
JP2022087255A (ja) キャリア結合剤組成物およびそれを作製および使用する方法
JP2021059593A (ja) 担体および抗体からなる組成物およびその製造および使用方法
RU2013155695A (ru) Препараты антител против с-мет
JP2024054251A (ja) ヒト成長分化因子15(gdf-15)の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
JP2018521135A5 (https=)
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
JP2014522843A5 (https=)
NZ630020A (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
JP2020537520A5 (https=)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
US20230203152A1 (en) Engineered anti-il-2 antibodies
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
JP2013543505A5 (https=)
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2014502955A5 (https=)